Evidence map›Paper›PMID 38481176›Full record

ArticleBMC ophthalmology2024

Long-term outcomes of anti-vascular endothelial growth factor therapy with and without posterior scleral reinforcement on myopic maculopathy in myopic choroidal neovascularization eyes.

Meng-Tian Kang, Ningli Wang, Wenjun Xu, Mayinuer Yusufu, Wu Liu, Jiaxin Tian, Yue Qi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Meng-Tian KangBeijing Tongren Hospital, Beijing Ophthalmology & Visual Science Key Lab, Beijing Tongren Eye Center, Capital Medical University, Beijing, China.
Ningli WangBeijing Tongren Hospital, Beijing Ophthalmology & Visual Science Key Lab, Beijing Tongren Eye Center, Capital Medical University, Beijing, China.
Wenjun XuBeijing Tongren Hospital, Beijing Ophthalmology & Visual Science Key Lab, Beijing Tongren Eye Center, Capital Medical University, Beijing, China.
Mayinuer YusufuCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Wu LiuBeijing Tongren Hospital, Beijing Ophthalmology & Visual Science Key Lab, Beijing Tongren Eye Center, Capital Medical University, Beijing, China.
Jiaxin TianBeijing Tongren Hospital, Beijing Ophthalmology & Visual Science Key Lab, Beijing Tongren Eye Center, Capital Medical University, Beijing, China.
Yue QiBeijing Tongren Hospital, Beijing Ophthalmology & Visual Science Key Lab, Beijing Tongren Eye Center, Capital Medical University, Beijing, China. qiyue@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-vascular endothelial growth factor (anti-VEGF) therapy is used for myopic choroidal neovascularization (mCNV). Patchy chorioretinal atrophy (pCRA) enlargement has been reported in mCNV cases associated with vision loss. Our aim was to compare the long-term effectiveness of anti-VEGF therapy alone versus anti-VEGF followed by posterior scleral reinforcement (PSR) in controlling myopic maculopathy in mCNV eyes.

methodsWe performed a retrospective review of the medical records of 95 high myopia patients (refractive error ≥ 6.00 diopters, axial length ≥ 26.0 mm) with mCNV. Patients were treated with anti-VEGF alone (group A) or anti-VEGF followed by PSR (group B). The following data were collected: refractive error, best corrected visual acuity (BCVA), ophthalmic fundus examination, ocular coherence tomography and ocular biometry at 12 and 24 months pre- and postoperatively. The primary outcomes were changes in pCRA and BCVA.

resultsIn 26 eyes of 24 patients, the mean pCRA size significantly increased from baseline (0.88 ± 1.69 mm

conclusionAnti-VEGF therapy followed by PSR achieved better outcomes than anti-VEGF therapy alone in controlling the development of myopic maculopathy in mCNV and may constitute a better treatment option by securing a better long-term VA outcome.

Indexed as

Choroidal NeovascularizationMacular DegenerationMyopia, DegenerativeRetinal DiseasesAngiogenesis InhibitorsEndothelial Growth FactorsFluorescein AngiographyHumansIntravitreal InjectionsRetrospective StudiesScleraTomography, Optical CoherenceVisual AcuityAngiogenesis InhibitorsEndothelial Growth FactorsAnti-vascular endothelial growth factorChoroidal neovascularizationMyopic maculopathyPosterior scleral reinforcement

Identifiers

PMID38481176
PMCPMC10938773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.